Last reviewed 2026-04-19 · How we verify

Gemcitabine plus rapamycin

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Addition of Everolimus to Standard of Care in Carcinoma Gallbladder (PHASE2, PHASE3)
• Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride (PHASE1)
• High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NA)
• Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer (PHASE1, PHASE2)
• Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine (PHASE1, PHASE2)
• Individualized Drug Treatment for Treating Patients With Pancreatic Cancer (PHASE2)
• Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) (PHASE1, PHASE2)
• Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.